Skip to content
Screener

Spyre Therapeutics, Inc. SYRE Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Absci Corporation logo
Absci CorporationABSI
$328K-51.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$624K-55.2%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$195K
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$1.43M+260%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$418K+186%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.05M-45.4%

Other financials

Income statement

See full
Revenue-
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$9.25B+904%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:00 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001636282-26-000050
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Acquired in-process research and development
Change in fair value of CVR liability30,270(2,400)
Gain on sale of in-process research and development asset(30,000)
Net accretion of discount on marketable securities(2,059)(2,642)
Interest proceeds from maturities of zero coupon U.S. Treasury Bills372530
Changes in operating assets and liabilities:
Accounts payable(3,212)3,023
Accrued and other liabilities3,653(5,998)

Item 1. Financial Statements (Unaudited).

FAQ

What is Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Spyre Therapeutics, Inc. (SYRE) reported accretion (amortization) of discounts and premiums, investments of $2.06M in Q1 2026.
How has Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 22.1% year-over-year, from $2.64M to $2.06M.
What is the long-term trend for Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 96.0% compound annual growth rate (CAGR), from -$548K to $8.09M.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to the carrying value of debt or investment securities purchased at a discount or premium. Over time, the discount or premium is amortized or accreted to reach the face value of the instrument at maturity. It is a standard adjustment to reconcile interest income or expense to actual cash flows.

Ask your AI about Spyre Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude